Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Dragonfly Therapeutics
GI Innovation, Inc.
Mayo Clinic
Merck Sharp & Dohme LLC
Gruppo Oncologico Italiano di Ricerca Clinica
H. Lee Moffitt Cancer Center and Research Institute
Alliance for Clinical Trials in Oncology
Neonc Technologies, Inc.
Eisai Inc.
Tizona Therapeutics, Inc
National Institutes of Health Clinical Center (CC)
Genentech, Inc.
Shanghai Henlius Biotech
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Werewolf Therapeutics, Inc.
Genenta Science
Merck Sharp & Dohme LLC
University of California, Davis
City of Hope Medical Center
ImmunityBio, Inc.
NRG Oncology
Novartis
Bayer
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Sairopa B.V.
University of Iowa
University of Washington
Merck Sharp & Dohme LLC
Hospital of Macerata
Yale University
University of California, San Francisco
Coherus Oncology, Inc.
Merck Sharp & Dohme LLC
University of Pittsburgh
Dragonfly Therapeutics
Nanobiotix
University of Alabama at Birmingham
ImmuneSensor Therapeutics Inc.
City of Hope Medical Center
Scancell Ltd
Vyriad, Inc.
Asher Biotherapeutics, Inc.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Merck Sharp & Dohme LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC